The interpretation of the updated American Urological Association guideline of interstitial cystitis/bladder pain syndrome in 2022
10.3760/cma.j.cn112139-20230713-00006
- VernacularTitle:2022版美国泌尿外科学会间质性膀胱炎/膀胱疼痛综合征指南更新解读
- Author:
Lei ZENG
1
;
Jianbin BI
Author Information
1. 中国医科大学附属第一医院泌尿外科，沈阳 110001
- Keywords:
Cystitis, interstitial;
Guidebooks;
Bladder pain syndrome;
Hunner lesion;
Update of guideline
- From:
Chinese Journal of Surgery
2024;62(2):122-127
- CountryChina
- Language:Chinese
-
Abstract:
In 2022, American Urological Association updated the guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). A significant change has been made in treatment recommendations. The updated guideline no longer divided treatments into first-line through sixth-line tiers. Instead, treatment is categorized into behavioral/non-pharmacologic, oral medicines, bladder instillations, procedures, and major surgery. This change emphasizes the heterogeneity of IC/BPS patients and the importance of individualized treatment, overturns traditional unreasonable ideas about hierarchical and progressive treatment, and encourages patients and physicians to make treatment decisions together. At the same time, the panel emphasized the importance of early implementation of cystoscopy in patients suspected of Hunner lesions and warned against the possibility of pentosan polysulfate causing a unique retinal pigmentary maculopathy. Urinary reconstruction surgery was considered to only be used as a last resort for the treatment of IC/BPS, and there is uncertainty about the overall balance between benefits and risks/burdens. The updated guideline provides a new understanding and decision-making basis for the diagnosis and treatment of IC/BPS. However, it should be noted that the clinical characteristics of Chinese patients should be considered in practice and the application of the guideline should be localized.
